Assessing the Self-reported After Events Following Immunization of COVID-19 Vaccines in Turkey and Bangladesh

Sultana, Arifa; Mim, Sabiha Rahman; Saha, Ananya; Yesmin, Fahmida; Tahsin, Md. Rafat; Bahar, Nasiba Binte; Fatema, Kazi Rubiya; Shahriar, Saimon; Prattay, Kazi Milenur Rahman; Rabbi, Fazle; Noushin, Fabiha; Samodder, Mithun; Sadia, Qurratul Ain; Ferdous, Jannatul; Mamun, Md Ariful Haque; Uddin, Mohammad Ikram; Akter, Tahmina; Rahman, Md. Mustafizur; Sarker, Md. Moklesur Rahman; Kuddus, Mohammed; Aktar, Fahima; Chowdhury, Jakir Ahmed; Chowdhury, Abu Asad; Kabir, Shaila; Büyüker, Sultan Mehtap; Rahman, Md. Sohanur; Rahman, Md. Habibur; Amran, Md. Shah

doi:10.1007/s11356-023-25527-2

Cited by 5 publications

(4 citation statements)

References 58 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, after the second dose, the percentage of AEs for Pfizer declined to 71.19%, whereas for Moderna, it was 86.09%. It is worth noting that while Pfizer and Moderna vaccines exhibited varying trends in AEs after the second dose, other vaccines such as Sinopharm, Sinovac, and Oxford-AstraZeneca demonstrated a significant reduction in AEs after the second dose during overall immunization [22]. For the AstraZeneca vaccine, this unusual trend of lower AEs after the second dose was also reported in two separate studies from the Kingdom of Saudi Arabia and the United Kingdom with large sample sizes [23,24].…”

Section: Discussionsupporting

confidence: 53%

Immediate and Long-Term Adverse Events of COVID-19 Vaccines: A One-Year Follow-Up Study From the Kurdistan Region of Iraq

Abdulkader,

Merza

2023

Cureus

View full text Add to dashboard Cite

BackgroundThe administration of COVID-19 vaccines has been critical in controlling the spread of the virus. However, understanding the potential adverse events (AEs) associated with these vaccines is crucial for public health. While most previous studies observed only short-term AEs, this study aimed to investigate the immediate and long-term AEs following the first and second doses of Pfizer, AstraZeneca, and Sinopharm vaccines, providing valuable long-term insights. MethodologyA prospective, one-year, follow-up study was conducted by tracking 922 vaccinated individuals to assess short-term and long-term AEs. Demographics, clinical characteristics, vaccine types, and dose effects were taken into consideration. AEs were classified based on severity and duration. Statistical analyses were performed to compare differences among the vaccine groups, with p-values <0.05 considered significant. Bowker's and chi-square tests were performed using JMP Pro 14.3.0. ResultsOf the 922 participants, 55.53% (n = 512) were vaccinated with Pfizer, and 23.32% (n = 215) and 21.15% (n = 195) were vaccinated with Sinopharm and AstraZeneca, respectively. Overall, 72.34% of participants (n = 667) were suffering from AEs after the first dose, with a lower prevalence of AEs after the second dose (52.71%, n = 486). Pfizer exhibited the highest percentage and severity of AEs, followed by AstraZeneca and Sinopharm. Most AEs reported in this study were mild and resolved within 72 hours, with females experiencing more frequent AEs. The common short-term AEs observed were fever, injection-site pain, myalgia, fatigue, and headache. Notably, there were no chronic AEs, and only one case of myocarditis was associated with AstraZeneca. ConclusionsDespite the variation in the prevalence of AEs among the three vaccines, the vaccination process proved to be safe with no serious short-term AEs. However, the long-term AEs associated with AstraZeneca and the decrease in the prevalence of AEs after the second dose of the COVID-19 vaccines warrant further investigations and priority for future research.

show abstract

Section: Discussionsupporting

confidence: 53%

Immediate and Long-Term Adverse Events of COVID-19 Vaccines: A One-Year Follow-Up Study From the Kurdistan Region of Iraq

Abdulkader,

Merza

2023

Cureus

View full text Add to dashboard Cite

show abstract

“…The Michels et al analysis found a nearly four-fold increase in cardiovascular SAEs among subjects in the Pfizer trial who received the BNT162b2 injection compared to placebo, a fact never reported to the public at the time of the rollouts in December 2020 [54]. Notwithstanding these grave concerns, the Moderna product has shown even more frequent AEs when compared to its Pfizer counterpart [116][117][118][119][120]135]. Both mRNA products were linked with increased risks of ischemic stroke, brain hemorrhage, acute coronary syndrome, and other conditions known to reduce life expectancy.…”

Section: Discussionmentioning

confidence: 99%

“…Whereas some authors have observed fewer AEs after the second dose [ 134 ], others have reported an increased incidence [ 116 ]. Sultana et al reported varying trends in AEs after the second dose for both mRNA products, albeit with a higher frequency of AEs following the second-dose administration of the Moderna vaccine [ 135 ].…”

Section: Reviewmentioning

confidence: 99%

COVID-19 mRNA Vaccines: Lessons Learned from the Registrational Trials and Global Vaccination Campaign

Mead,

Seneff,

Wolfinger

et al. 2024

Cureus

View full text Add to dashboard Cite

Our understanding of COVID-19 vaccinations and their impact on health and mortality has evolved substantially since the first vaccine rollouts. Published reports from the original randomized phase 3 trials concluded that the COVID-19 mRNA vaccines could greatly reduce COVID-19 symptoms. In the interim, problems with the methods, execution, and reporting of these pivotal trials have emerged. Re-analysis of the Pfizer trial data identified statistically significant increases in serious adverse events (SAEs) in the vaccine group. Numerous SAEs were identified following the Emergency Use Authorization (EUA), including death, cancer, cardiac events, and various autoimmune, hematological, reproductive, and neurological disorders. Furthermore, these products never underwent adequate safety and toxicological testing in accordance with previously established scientific standards. Among the other major topics addressed in this narrative review are the published analyses of serious harms to humans, quality control issues and process-related impurities, mechanisms underlying adverse events (AEs), the immunologic basis for vaccine inefficacy, and concerning mortality trends based on the registrational trial data. The risk-benefit imbalance substantiated by the evidence to date contraindicates further booster injections and suggests that, at a minimum, the mRNA injections should be removed from the childhood immunization program until proper safety and toxicological studies are conducted. Federal agency approval of the COVID-19 mRNA vaccines on a blanket-coverage population-wide basis had no support from an honest assessment of all relevant registrational data and commensurate consideration of risks versus benefits. Given the extensive, well-documented SAEs and unacceptably high harm-to-reward ratio, we urge governments to endorse a global moratorium on the modified mRNA products until all relevant questions pertaining to causality, residual DNA, and aberrant protein production are answered.

show abstract

“…Conversely, close-ended questions restrict the range of potential answers by offering predefined choices, potentially constraining the accuracy and depth of responses (Taherdoost, 2022). Combined method is also can be found in a similar study to obtain the participants opinion on post-vaccination experienced (Sultana et al, 2023).…”

Section: Discussionmentioning

confidence: 99%

Validity and Reliability of the Pfizer Booster Vaccine Effectiveness Questionnaire

Muhammad,

Ramatillah

2023

Contagion

View full text Add to dashboard Cite

<div><table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td align="left" valign="top"><p><em>Vaccination is the right method to deal with the increasing number of infections due to COVID-19. One method for assessing the effectiveness of a vaccine is by using a questionnaire. This pilot study was conducted to assess the validity and reliability of the Pfizer booster vaccine effectiveness questionnaire in Indonesia. The pilot study was carried out cross-sectionally using a new questionnaire that had not been tested for validity and reliability. The validity test of the questionnaire was carried out using the modified Delphi method which 3 professional will determine whether the questionnaire is valid to be used while in reliability analysis using inter reliability consistency analysis with score not less than < 0.3. Based on the collected data, there are 25 (62.5%) female respondents and 15 (37.5%) male respondents. With the age of majority <30 years as many as 37 (92.5%) respondents, <45 as many as 2 (5%) respondents and >45 as many as 1 (2.5%) person.. In the validity test, 3 experts stated that the questionnaire is considered to be valid and suitable for use in research. Before checking the inter reliability consistency there were 50 questions but after the analysis only 12 questions were considered reliable to be used with Cronbach's alpha score 0.797. Of the 12 questions, there were 3 questions on sociodemography, 3 questions on side effects, 4 questions on allergy history, and 2 questions on data regarding history of COVID-19 infection. It can be concluded that the questions are considered valid by 3 experts and has 12 reliable questions in this questionnaire with Cronbach's alpha of 0.797. Although it functions as a pilot study for questionnaire development, its significance lies in the potential to enhance our understanding of the various factors that impact the effectivness of the pfizer booster vaccine, specifically within the Indonesian population.</em></p><p><em><br /></em></p></td></tr></tbody></table></div><p><strong><em>Keyword: Cronbach’s Alpha, Pfizer, Reliability, Vaccines, Validity</em></strong></p>

show abstract

Assessing the Self-reported After Events Following Immunization of COVID-19 Vaccines in Turkey and Bangladesh

Cited by 5 publications

References 58 publications

Immediate and Long-Term Adverse Events of COVID-19 Vaccines: A One-Year Follow-Up Study From the Kurdistan Region of Iraq

Immediate and Long-Term Adverse Events of COVID-19 Vaccines: A One-Year Follow-Up Study From the Kurdistan Region of Iraq

COVID-19 mRNA Vaccines: Lessons Learned from the Registrational Trials and Global Vaccination Campaign

Validity and Reliability of the Pfizer Booster Vaccine Effectiveness Questionnaire

Contact Info

Product

Resources

About